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 Background There is no method routinely used to predict response to anthracycline and cyclophosphamide–based chemo-
therapy in the clinic; therefore patients often receive treatment for breast cancer with no benefit. Loss of the 
Fanconi anemia/BRCA (FA/BRCA) DNA damage response (DDR) pathway occurs in approximately 25% of breast 
cancer patients through several mechanisms and results in sensitization to DNA-damaging agents. The aim of this 
study was to develop an assay to detect DDR-deficient tumors associated with loss of the FA/BRCA pathway, for 
the purpose of treatment selection.
 Methods DNA microarray data from 21 FA patients and 11 control subjects were analyzed to identify genetic processes 
associated with a deficiency in DDR. Unsupervised hierarchical clustering was then performed using 60 BRCA1/2 
mutant and 47 sporadic tumor samples, and a molecular subgroup was identified that was defined by the molecu-
lar processes represented within FA patients. A 44-gene microarray-based assay (the DDR deficiency assay) was 
developed to prospectively identify this subgroup from formalin-fixed, paraffin-embedded samples. All statistical 
tests were two-sided.
 Results In a publicly available independent cohort of 203 patients, the assay predicted complete pathologic response vs 
residual disease after neoadjuvant DNA-damaging chemotherapy (5-fluorouracil, anthracycline, and cyclophos-
phamide) with an odds ratio of 3.96 (95% confidence interval [Cl] =1.67 to 9.41; P = .002). In a new independent 
cohort of 191 breast cancer patients treated with adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide, a 
positive assay result predicted 5-year relapse-free survival with a hazard ratio of 0.37 (95% Cl = 0.15 to 0.88; 
P = .03) compared with the assay negative population.
 Conclusions A formalin-fixed, paraffin-embedded tissue-based assay has been developed and independently validated as a 
predictor of response and prognosis after anthracycline/cyclophosphamide–based chemotherapy in the neoadju-
vant and adjuvant settings. These findings warrant further validation in a prospective clinical study.
  JNCI J Natl Cancer Inst (2014) 106(1): djt335
Most chemotherapy regimens used for breast cancer in the adjuvant, 
neoadjuvant, or advanced settings contain agents that directly damage 
DNA, such as anthracyclines (epirubicin or doxorubicin) and alkylat-
ing agents (cyclophosphamide). Approximately 20% to 40% of early 
breast cancer patients have a complete clinical response and 10% 
have a complete pathological response (pCR) to these regimens (1–3), 
most likely because of a deficiency in normal DNA damage response 
(DDR) pathways (4,5). Many patients, however, do not respond and 
may not gain any benefit from this type of chemotherapy. In spite of 
this, there is no reliable method for predicting DDR deficiency from 
diagnostic material for the purpose of patient treatment selection.
One of the major DDR pathways disrupted in breast cancer is 
the Fanconi anemia (FA)/BRCA pathway (6). This pathway was 
first described as lost in a rare autosomal recessive condition char-
acterized by extreme sensitivity to DNA-damaging agents (7). The 
FA/BRCA pathway coordinates the repair of stalled DNA replica-
tion after DNA damage and is therefore important for cancer cell 
survival after therapeutic DNA-damaging agents such as anthracy-
clines and cyclophosphamide (5,8). It is estimated to be deficient 
in approximately 25% of breast cancer patients through mutation 
or epigenetic silencing of several key components, including the 
BRCA1 and BRCA2 genes (9).
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Although identification of FA/BRCA pathway–deficient, and 
therefore DDR-deficient, tumors could allow the selection of 
patients for anthracycline/cyclophosphamide–based chemotherapy 
treatment, the multiple mechanisms through which the pathway 
can be lost has made it difficult to develop assays suitable for clinical 
use. In this study, it was hypothesized that although the FA/BRCA 
pathway can be compromised by multiple mutational or epigenetic 
events, the resultant accumulation of DNA damage might activate 
common genetic processes, thereby defining a distinct molecu-
lar subgroup. Furthermore, an assay that identified this subgroup 
could predict which patients would benefit from chemotherapy. 
Taking this approach, a novel DDR deficiency (DDRD) assay that 
can be applied prospectively to patient samples has been developed 
and independently validated.
Methods
Patient samples
A public microarray dataset (Supplementary Table  1, available 
online) generated from bone marrow of 21 FA patients and 11 
healthy control subjects (10) was used to define the molecular pro-
cesses associated with FA/BRCA pathway dysfunction.
For subgroup identification, a dataset of 107 formalin-fixed, 
paraffin-embedded (FFPE) breast cancer samples enriched with 
60 BRCA1/2 mutant tumors were collected in the Mayo Clinic, 
Rochester, Minnesota, after ethical approval from the Mayo 
Institutional Review Board. Sporadic control samples were 
matched to BRCA mutant samples based upon patient age at diag-
nosis, estrogen receptor (ER) and progesterone receptor (PR) sta-
tus, FFPE block age, and diagnosis.The clinical parameters for the 
BRCA1/2 mutant and sporadic control sample set are provided in 
Supplementary Table 2 (available online).
The assay’s ability to predict pCR was assessed in the neoadju-
vant setting using microarray data from 203 patients available in 3 
public datasets. The first (11) and second (12) datasets were com-
prised of 86 and 51 ER-positive and ER-negative primary breast 
tumor samples, respectively, collected before treatment with fluoro-
uracil, doxorubicin, and cyclophosphamide (FAC) (Supplementary 
Tables 3 and 4, available online). The third (13) was comprised of 
66 ER-negative primary breast tumor samples collected before 
5-fluorouracil, epirubicin, and cyclophosphamide (FEC) treatment 
(Supplementary Table 5, available online).
The assay’s ability to predict recurrence-free survival at 5 years 
after surgery was assessed in the adjuvant setting using an inde-
pendent dataset of 191 N0-N1 ER-positive and ER-negative 
FFPE patient samples with a median follow-up of 4.93  years 
(Supplementary Table  6, available online). Historically, N0 and 
N1 patients were treated with adjuvant FEC; ER-positive patients 
also received hormone therapy. Among HER2-positive patients, 
83.3% received 1 year of adjuvant trastuzumab. ER and PR sta-
tus was determined by immunohistochemistry using the Quick 
Score method. T stage was determined according to the American 
Joint Committee on cancer TNM staging system (14). Tumor 
grade was defined according to the Nottingham grading system 
(15). HER2 status was assessed by immunohistochemistry: a score 
of 0 or 1 was negative; score of 3 was positive; and a score of 2 
led to further assessment by chromogenic in situ hybridisation 
and was considered positive if HER2 amplification was detected. 
Lymphocytic infiltrate was determined by lymphocyte count of 
hematoxylin and eosin–stained full face sections.
The prognostic utility of the assay to predict recurrence-free 
survival was assessed using three public datasets (16–18) totalling 
664 ER-positive and ER-negative patients that did not receive 
DNA-damaging chemotherapy with a median follow-up of 
7.3  years (Supplementary Tables 7–9, available online). Of these 
patients, 64 received tamoxifen.
Supplementary Tables 1–9 provide the sample names and clini-
cal information required to reproduce the results in this article 
for each dataset used in this study. The distribution of the clinical 
parameters within the training and validation datasets used within 
this study are provided within Supplementary Table 10 (available 
online). The publicly sourced FA dataset and neoadjuvant and 
prognostic validation datasets can be accessed using the GEO 
accession numbers provided within the Supplementary Materials 
(available online). Subgroup analysis based upon major ethnic 
groups was not performed because these data were not available 
for the tumor datasets. Flow diagrams of the discovery and valida-
tion of the DDRD assay is provided in Supplementary Figures 1 
and 2 (available online).
Written informed consent was obtained for all tissue samples used.
Gene Expression Profiling
Total RNA was extracted from macrodissected FFPE tumor 
samples using the Roche High Pure RNA Paraffin Kit (Roche 
Diagnostics, Burgess Hill, UK) as described previously (19). Total 
RNA was amplified using the NuGEN WT-Ovation FFPE System 
(NuGEN, San Carlos, CA) and hybridized to the Almac Breast 
Cancer DSA (Affymetrix, Santa Clara, CA) as described previously 
(19,20).
Statistical Analysis Methods
Differentially expressed probesets between 21 FA patients and 
11 healthy control subjects were identified using a fold-change 
threshold of absolute fold-change greater than 3 and a statisti-
cally significant t test P value threshold adjusted for false discovery 
rate of less than .001 (Supplementary Table 11, available online) 
(21). Statistically significantly enriched functional classes with a 
P value adjusted for false discovery rate of less than .05 [derived 
using the hypergeometric distribution test (22)] corresponding to 
differentially expressed genes were determined using the experi-
ment analysis workflow from Metacore (GeneGo; Carlsbad, CA) 
(Supplementary Table 12, available online).
BRCA1/2 mutant and sporadic control training samples were 
split into 2 datasets based on the transcript levels of ESR1 (estrogen 
receptor 1); details are provided in the Supplementary Materials 
(available online). A combined background and variance filter was 
applied to each dataset (ER-negative and ER-positive) to iden-
tify the most variable probesets (Supplementary Tables 13 and 
14, available online). Hierarchical clustering (Pearson correlation 
distance and Ward’s linkage) was applied to probesets and sam-
ples from each dataset separately. The number of subclusters was 
determined using the gap statistic (23). The sample clusters from 
the ER-positive and ER-negative datasets representing molecu-
lar processes identified in FA patient samples were selected for 
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classification and labeled as DDRD-positive; the remaining sam-
ples were labeled as DDRD-negative.
Signature generation was performed using the partial least 
squares method (24) with selection of features based on recursive 
feature elimination during 10 repeats of fivefold cross-validation 
(Supplementary Figure  3, available online). Model development 
was nested within cross-validation, including an initial filter to 
remove 75% of probesets with the lowest variance and intensity, 
reference-based robust multichip averaging preprocessing, and 
recursive feature elimination discarding the least important 10% of 
probesets at each iteration. The total number of features in the final 
model was determined by the feature length maximizing the aver-
age area under the receiver operating characteristics curve under 
cross-validation. To facilitate validation of the signature across 
multiple microarray platforms, the selected probeset signature was 
regenerated at the gene level (Supplementary Tables 15–17, avail-
able online). The threshold for dichotomization of the predictions 
was selected to maximize the sum of sensitivity and specificity from 
cross-validated training data (Supplementary Figure 3D, available 
online).
To calculate negative and positive predictive value within the 
training and neoadjuvant validation datasets, the prevalence of each 
endpoint (BRCA status/pCR) was estimated using the proportions 
of each class in the corresponding dataset. Supplementary Table 18 
(available online) lists the priors for the training and each individ-
ual neoadjuvant dataset.
A logistic regression model was used to estimate the odds ratio 
(OR) comparing the odds of pCR in DDRD-positive vs DDRD-
negative patients. Cox proportional hazards regression was used to 
investigate the prognostic effect of the DDRD signature on recur-
rence-free survival at 5  years after surgery. The estimated effect 
of the signature was adjusted for tumor stage, ER status, HER2 
status, age, nodal status, and tumor grade by fitting a multivari-
able (logistic regression or Cox proportional hazards regression) 
model. The proportional hazard assumption was verified for the 
Cox model using a formal statistical test based on the Schoenfeld 
residuals (25). The P value for the test was calculated for origi-
nal, log-transformed, and rank time scales. Samples with unknown 
clinical factors were excluded in this assessment.
All tests of statistical significance were two-sided and performed 
at a 5% alpha level.
Further details are available in the Supplementary Methods 
(available online).
results
Identification of a DDRD Molecular Subgroup in 
Breast Cancer
The biological processes modulated in response to loss of compo-
nents of the FA/BRCA pathway were identified after analysis of a 
publicly available dataset from FA patients and healthy control 
subjects (10) and were found to be predominantly immune related 
(Supplementary Table  12, available online). To identify molecular 
subgroups in breast cancer defined by the same processes as those 
identified in FA patients, a DNA-microarray platform optimized for 
FFPE tissue (20) was used to analyze a BRCA1/2 mutant–enriched 
cohort of FFPE breast cancer samples. Molecular subgroups were 
identified using an unsupervised hierarchical clustering approach. 
ER-positive and ER-negative cohorts were considered separately 
because the dominant effect of the ER on hierarchical clustering 
(26) could prevent the identification of an ER-independent sub-
group. Probeset lists displaying the most variation across the tumors 
were selected (Supplementary Tables 13 and 14, available online). 
A total of 6 probeset clusters and 3 sample groups were identified 
within the ER-negative dataset (Figure 1A), and 6 probeset clusters 
and 5 sample groups were identified within the ER-positive dataset 
(Figure 1B). Pathway analysis and molecular process characteriza-
tion (Supplementary Tables 19 and 20, available online) identified 
probeset cluster 3 within the ER-negative cohort and probeset clus-
ter 6 within the ER-positive cohort as representing the molecular 
processes (predominantly immune related) identified in FA patient 
samples, sharing 14 (Figure  1C; Supplementary Table  21, avail-
able online) and 13 (Figure 1D; Supplementary Table 22, available 
online) statistically significantly enriched processes, respectively.
Using these data, a putative DDRD subgroup was generated 
by combining samples defined by the FA/BRCA–deficient biology: 
sample group B as defined by probeset cluster 3 in ER-negative sam-
ples (Figure 1A) and sample groups B and C as defined by probeset 
cluster 6 in ER-positive samples (Figure 1B). Pathway analysis of 
the genes differentially expressed between the tumors contained 
within the DDRD subgroup and the remaining tumors within the 
training set confirmed that immune signaling was the predominant 
biology associated with this subgroup (Supplementary Table  23, 
available online).
Development of an Assay to Identify the DDRD 
Subgroup
The putative DDRD subgroup was class-labeled DDRD-positive, 
whereas the remaining samples were class-labeled DDRD-
negative. Computational classification resulted in a 44-gene assay 
that could be used to prospectively identify clinical samples within 
the DDRD molecular subgroup, referred to herein as the DDRD 
assay (Supplementary Table 17 and Supplementary Figure 3, avail-
able online). In the training set, the assay predicted BRCA1/2 
mutational status with a specificity of 0.79 (95% confidence interval 
(Cl) = 0.64 to 0.86) and sensitivity of 0.58 (95% Cl = 0.48 to 0.65) 
(Table 1; Supplementary Figure 4A, available online),  confirming 
an association between DDRD assay positivity and dysfunction of 
the FA/BRCA pathway.
Validation of the DDRD Assay in Predicting Response to 
Neoadjuvant Anthracycline-Based Chemotherapy
To assess the ability of the DDRD assay to predict response to 
DNA-damaging chemotherapy, it was applied to 3 microarray 
datasets (11–13). In each study, patients were treated with neoad-
juvant 5-fluorouracil, anthracycline, and cyclophosphamide–based 
regimens (Supplementary Tables 3–5, available online), and the 
endpoints were pCR or residual disease.
Multivariable analysis in the combined neoadjuvant dataset 
demonstrated that the DDRD assay predicted response in the 
DDRD-positive sample cohort relative to the DDRD-negative 
sample cohort independent of and superior to ER status, T stage, 
and grade (OR = 3.96; 95% Cl =1.67 to 9.41; P = .002) (Table 2; 
Supplementary Figure  4B, available online). The performance 
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metrics of the DDRD assay within each individual neoadjuvant 
dataset are provided in Supplementary Table 24 and Supplementary 
Figure 4, C–E (available online).
Clinical risk groups were defined by a response classifier based 
upon a logistic regression model of ER status, age, stage, and grade. 
Within each risk group, pCR rates were stratified by DDRD sta-
tus further confirming the independent association of DDRD-
positivity with pCR (Supplementary Table  25, available online). 
HER2 status was not assessed in this analysis as there was an insuf-
ficient number of samples with HER2 status information available.
Validation of the DDRD Assay in Predicting Clinical 
Outcome After Adjuvant FEC Chemotherapy
The assay was applied to FFPE samples from an independent 
validation cohort of breast cancer (N0–N1) patients who received 
adjuvant FEC chemotherapy. Overall, DDRD-positive patients had 
improved relapse-free survival relative to DDRD-negative patients 
with a 5-year hazard ratio (HR) of 0.37 (95% Cl = 0.15 to 0.88; 
P = .03) on multivariable analysis (Figure 2A; Table 3). Importantly, 
the assay predicted outcome better than and independent of ER 
status, HER2 status, T stage, grade, nodal status, and age (Table 3).
The precision of the DDRD assay was also evaluated following 
Clinical and Laboratory Standards Institute guidelines (27). This 
demonstrated that the total standard deviation estimates of samples 
spanning the DDRD assay’s score range were acceptable for clini-
cal application because they are less than 5% of the DDRD assay’s 
reportable range (see Supplementary Material, available online).
To determine whether the DDRD assay was prognostic inde-
pendent of treatment, it was applied to 3 publicly available early 
breast cancer datasets where patients had no cytotoxic chemo-
therapy (16–18) (Supplementary Tables 7–9, available online). No 
difference in survival was noted between the DDRD-positive and 
DDRD-negative populations (HR = 1.07; 95% Cl = 0.83 to 1.36; 
P = .61) (Figure 2B), confirming that the assay predicts patient out-
come in breast cancer only in the context of FEC chemotherapy.
Assessment of the Association Between ER and HER2 
Status With DDRD Assay Result
Because ER-negative tumors are more frequently sensitive to 
DNA-damaging chemotherapy than ER-positive tumors, the 
proportion of each population classified as DDRD-positive was 
assessed (Table 4). Consistent with what has been observed in the 
Figure  1. Hierarchical analysis of BRCA1/2 mutant and sporadic wild-
type control breast cancer samples. Hierarchical analysis of estrogen 
receptor (ER)–negative (A) and ER-positive (B) BRCA1/2 mutant and 
sporadic wild-type control breast cancer samples. Probeset cluster 
groups are annotated on the right side. Pathway analysis of each probe-
set cluster group and the number of biological processes each probeset 
cluster group has in common with Fanconi anemia (FA) patients are 
annotated on the left side of each image. Molecular subgroups are 
labeled A–C for ER-negative samples and A–E for ER-positive samples. 
The legend for each image indicates the BRCA1/2 mutational status and 
the DNA damage response deficiency (DDRD) assay group each sam-
ple was assigned to for assay generation. C and D) Demonstration of 
the statistically significant common molecular processes between FA 
patient samples and cluster 3 of ER-negative samples and cluster 6 of 
ER-positive samples respectively. The bars represent the –log P value of 
statistical significance for each process in both the FA patient and breast 
cancer samples. P values are derived from the two-sided hypergeomet-
ric distribution test.
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Figure 1. Continued
clinic, more ER-negative patients than ER-positive patients were 
DDRD-positive (52.0% vs 25.0%, P < .001; 67.9% vs 24.3%, P < 
.001 in the adjuvant dataset and neoadjuvant datasets, respectively). 
There was no statistically significant increase in DDRD positivity 
in HER2-positive patients (41.3% of HER2-positive vs 32.0% of 
HER2-negative; P = .26) in the adjuvant dataset.
Assessment of the Association Between Immune 
Infiltration and DDRD Assay Result
It has previously been observed that lymphocytic infiltration (LI) 
associates with an increased sensitivity to chemotherapy (28). 
Because the DDRD molecular subgroup is largely defined by 
immune signaling, it was important to confirm that the assay signal 
was arising from tumor cells and not from lymphocytes. The asso-
ciation between the assay score and LI was therefore assessed in 
the adjuvant dataset. A statistically significant association between 
DDRD positivity and LI was observed (P < .001); however, 43 case 
patients out of 155 with no LI were classified as DDRD-positive 
and 9 case patients out of 35 with LI were classified as DDRD-
negative. These data suggest that the DDRD assay does not 
directly represent LI.
To further assess whether the upregulation of immune signal-
ing measured by the assay originated from DDRD tumor cells, the 
assay score of laboratory cell-line models representative of DDRD 
positivity (BRCA1 mutant HCC1937 empty vector control breast 
cancer cell line [29] as well as RKO-FANCC knockout and RKO-
FANCG knockout colon cancer cell lines) vs DDRD-negative 
controls (HCC1937 cells in which BRCA1 was corrected and the 
RKO parental cell line) was assessed. In each case, the DDRD-
positive cell line displayed a statistically significantly higher assay 
score when compared with the control cell lines (Supplementary 
Figure 5 and Supplementary Table 26, available online).
Table 1. Performance metrics of the DNA damage response deficiency (DDRD) assay within the training dataset*
Prediction of BRCA mutation status using the DDRD assay
Dataset Sample No. Clinical outcome AUC (95% CI) ACC (95% CI) SENS (95% CI) SPEC (95% CI) PPV (95% CI) NPV (95% CI)
Training 107 BRCA mutant V 
wildtype
0.68  
(0.56 to 0.78)
0.70  
(0.57 to 0.76)
0.58  
(0.48 to 0.65)
0.79  
(0.64 to 0.86)
0.78  
(0.63 to 0.85)
0.60  
(0.49 to 0.65)
* The 95% confidence intervals (CIs) are from ±2 standard deviations from cross-validation. ACC = accuracy; AUC = area under the receiver operating characteristics 
curve; NPV = negative predictive value; PPV = positive predictive value; SENS = sensitivity; SPEC = specificity;.
Table 2. Multivariable analysis of the predictive value of the DNA 
damage response deficiency (DDRD) assay for pathological com-
plete response within the neoadjuvant fluorouracil, doxorubicin, 
and cyclophosphamide/5-fluorouracil, epirubicin, and cyclophos-
phamide validation dataset*
Parameter
Multivariable analysis 
OR (95% CI) P
DDRD-positive 3.96 (1.67 to 9.41) .002
ER-negative 2.93 (0.94 to 9.08) .06
Grade (3 vs 2) 2.19 (0.95 to 5.07) .07
T stage .32
  T1 1.00 (referent)
  T2 0.60 (0.08 to 4.44)
  T3 0.45 (0.06 to 3.50)
  T4 0.09 (0.01 to 1.67)
* Logistic regression was used to estimate the odds ratio (OR) and its 95% 
confidence interval (CI). DDRD-negative, ER-positive, grade level 2, and 
T stage 1 were the baseline (referent) or comparative levels. P values are 
derived from the two-sided Wald test. ER = estrogen receptor.
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Figure  2. Kaplan–Meier time to recurrence curves stratified by the 
DNA damage response deficiency (DDRD) assay. Kaplan–Meier 
time to recurrence curves censored at 5 years for 191 breast cancer 
patients treated with adjuvant 5-fluorouracil, epirubicin, and cyclo-
phosphamide (FEC) (A) and 664 early breast cancer patients from 
3 studies (14–16) in which patients did not receive DNA-damaging 
chemotherapy (B). P values are derived from the two-sided Wald 
test. The number of events/patients at risk at various time intervals 
are noted in the tables below the curves. CI  =  confidence interval; 
HR = hazard ratio.
Together these data support the model that the immune signal-
ing defining the DDRD subgroup and assay arises directly from 
tumor cells and this can be associated with LI.
Discussion
This study describes a 44-transcript assay that prospectively iden-
tifies a molecular subgroup of breast cancers deficient in the FA/
BRCA DDR pathway and sensitive to anthracycline/cyclophospha-
mide–based chemotherapy. In the neoadjuvant setting, the DDRD 
assay was found to statistically significantly predict pCR to FAC/
FEC. Stratification of pCR rates by ER status or a logistic regression 
model developed using standard clinical risk factors demonstrated 
the DDRD assay positively associated with increased response 
within each stratified group. In the adjuvant setting, the assay was 
prognostic in the context of FEC chemotherapy and was not prog-
nostic in the absence of chemotherapy. Importantly, the assay pro-
vided additional information when assessed by multivariable analysis 
against other prognostic factors commonly assessed in the clinic.
To improve the ability to detect a FA/BRCA pathway–defi-
cient subgroup, the training cohort of primary breast tumors was 
enriched with known BRCA1/2 mutant tumors. Interestingly, not 
all of the BRCA1/2 mutant samples fell within the DDRD sub-
group, and 32.5% of DDRD-positive tumors were BRCA1/2 wild-
type. This is consistent with what is observed in the clinic, as not all 
BRCA1/2 mutant tumors are sensitive to DNA-damaging agents. 
This may be because not all reported mutations affect DNA repair 
(30) or could be because of alternative mechanisms compensating 
for the DDR deficiency. Also not all BRCA1/2 wild-type tumors 
possess a normal DDR because epigenetic silencing of BRCA1/2 
as well as loss of other components of the FA/BRCA pathway can 
result in DNA damage sensitivity (9).
Table 3. Multivariable analysis of the predictive value of the DNA 
damage response deficiency (DDRD) assay for relapse-free sur-
vival 5 years after fluorouracil, epirubicin, and cyclophosphamide 
chemotherapy*
Parameter
Multivariable analysis 
HR (95% CI) P
DDRD-positive 0.37 (0.15 to 0.88) .03
ER-negative 0.46 (0.20 to 1.06) .07
HER2-positive 1.72 (0.79 to 3.73) .17
Age 0.59 (0.32 to 1.08) .09
Grade (3 vs 1 and 2)† 1.14 (0.48 to 2.71) .77
T stage .40
  T1 1.00 (referent)
  T2 0.63 (0.29 to 1.40)
  T3 1.13 (0.35 to 3.65)
Nodal status .97
  N0 1.00 (referent)
  N1 1.02 (0.47 to 2.21)
* Cox proportional hazard model used to calculate hazard ratio (HR) and 95% 
confidence interval (CI). DDRD-negative, ER-negative, grade level 1 and 2, T 
stage 1, HER2-negative, and nodal status N0 were the baseline (referent) or 
comparative levels. Age was continuous with parameter estimate for a 16-year 
difference in age (representing ratio of hazard between patients at the 1st 
and 3rd quartiles of age distribution). P values are derived from the two-sided 
Wald test. ER = estrogen receptor.
† Grade 1 and 2 were combined because of small number of grade 1 patients.
Table  4.  Association of the DNA damage response deficiency 
(DDRD) assay with estrogen receptor (ER) status, HER2 status, and 
lymphocytic infiltration within validation datasets
Adjuvant dataset Total No.
DDRD- 
positive, % P*
Adjuvant
  ER-positive 112 25.0 <.001
  ER-negative 77 52.0
  HER2-positive 46 41.3 .26
  HER2-negative 128 32.0
  Triple negative 44 54.6 .001
  Non–triple negative 135 28.2
Lymphocytic infiltrate  
positive
35 74.3 <.001
Lymphocytic infiltrate  
negative
155 27.7
Neoadjuvant
  ER-positive 70 24.3 <.001
  ER-negative 134 67.9
* A two-sided χ2 test was used to assess the statistical significance of the 
univariate association between the DDRD assay and each clinical factor.
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Cell-line models representative of loss of the FA/BRCA pathway 
demonstrated a high DDRD score, indicating that the immune signal 
arises directly from tumor cells. Interestingly, LI has been reported 
in BRCA1 mutant cancers (31), and it has been reported that LI, as 
assessed on standard histopathology, associates with chemotherapy 
response (28), although there is only moderate interobserver agree-
ment with this measurement (kappa = 0.6) (32). Although there was 
an association between the DDRD result and LI in this study, this 
was not absolute, indicating that one was not interchangeable for 
the other. The immune infiltrate may, however, be in response to 
the immune signal originating from DDRD tumor cells. In support 
of this, there is increasing evidence that damaged DNA, as occurs 
spontaneously in FA/BRCA–deficient tumors, can activate immune 
pathways similar to viral infection (33). Indeed, it has recently been 
reported that expression of a collection of immune genes associates 
with response to anthracycline-based chemotherapy in publically 
available datasets (34). Interestingly seven of these genes—CXCL10, 
MX1, IDO1, IFI44L, CD2, ETV7 and RSAD2—are also present in 
the DDRD assay. CXCL10 has recently been reported to be upreg-
ulated in BRCA1-deficient breast cancers, further supporting a 
link between a specific immune response and loss of the FA/BRCA 
pathway (35). It is therefore hypothesized that the DDRD assay 
identifies tumors with endogenous DNA damage secondary to an 
abnormal DDR, with resultant upregulation of immune signaling, 
failed senescence, and possible lymphocyte activation.
Triple negativity (estrogen, progesterone, and HER2 receptor 
negativity) has been suggested as a biomarker for abnormal DDR 
and therefore response to DNA-damaging therapies (36). Upon 
multivariable analysis, however, a positive DDRD result was found 
to predict outcome in the neoadjuvant and adjuvant settings inde-
pendent of the ER status, indicating that triple negativity is distinct 
from a positive DDRD result.
There are conflicting data regarding the use of HER2 or the 
related TOP2A amplification as predictive markers of response 
to anthracyclines. In this study, we did not observe a statistically 
significant association between a positive result for DDRD and 
HER2 positivity (P  =  .26). Interestingly a large meta-analysis of 
3452 breast cancer patients treated with adjuvant chemotherapy 
advised against the routine use of HER2 or TOP2A amplification 
as a selection biomarker for anthracycline-based regimens because 
women with non-HER2– amplified tumors still benefited from 
treatment (37). In the adjuvant dataset, we observed that 32.0% of 
HER2-negative patients were DDRD-positive and would there-
fore be predicted to have an increased probability of benefiting 
from DNA-damaging chemotherapy. Consistent with this, the 
DDRD assay provided prognostic information independent from 
HER2 status in the multivariable analysis of known clinical fac-
tors in the adjuvant dataset. Unfortunately the HER2 status was 
not available for a sufficient number of samples in the neoadjuvant 
chemotherapy dataset to further assess the interaction between 
HER2, DDRD, and anthracycline response in this setting. A recent 
publication may explain some of the inconsistencies around HER2 
and TOP2A as predictive biomarkers. Chromosomal instabil-
ity associates with a benefit from anthracyclines in breast cancer 
and can result in the amplification of chromosome 17 on which 
the TOP2A and HER2 genes are located. This study suggests that 
the mechanism of sensitivity to anthracyclines is not the level of 
HER2 or TOP2A expression but rather the underlying chromo-
somal instability (38). Interestingly loss of the FA/BRCA pathway 
is associated with chromosomal instability (39–41), which provides 
further evidence for the link between the DDRD molecular sub-
group and DNA-damaging chemotherapy response.
The approach to developing a biomarker of benefit from DNA-
damaging chemotherapy presented in this study is different to 
that adopted by others. The DDRD assay is based upon a molecu-
lar subgroup discovered by unsupervised hierarchical clustering 
and is applicable to FFPE tumor sections routinely taken before 
the administration of chemotherapy. Others have demonstrated 
molecular subtypes that associate with chemosensitivity but, unlike 
this study, have not developed these into assays that could be used 
to analyze FFPE tissue in a prospective manner (34,42).
A potential limitation of this study is that the validation of the 
assay in the adjuvant treatment setting was performed in a historical 
cohort of N0 and N1 patients to allow adequate follow-up for recur-
rence. In modern practice, there has been a move toward offering 
chemotherapy to lower-risk patients who may be underrepresented 
in this dataset. Also in modern practice, N1 patients commonly 
receive a taxane in the adjuvant setting. Additionally, although the 
neoadjuvant dataset supports the predictive utility of the assay and the 
non-chemotherapy-treated dataset suggests the assay is not prognos-
tic for untreated patients, we acknowledge that the best study design 
to demonstrate its utility as a predictive assay in the adjuvant setting 
would be a prospective biomarker–treatment interaction design (43).
In summary, we have discovered a DDRD molecular subgroup 
in breast cancer that is predominantly defined by upregulation of 
immune signaling and can be identified by a 44-transcript DDRD 
assay. This assay has been demonstrated to predict increased tumor 
response and decreased recurrence after FEC/FAC chemotherapy. 
We hypothesize that patients classified as DDRD-negative may 
not respond to the same extent as DDRD-positive patients from 
anthracycline/cyclophosphamide–based treatment and may there-
fore benefit from alternative approaches such as taxane-based 
regimens. This could be investigated further using samples from 
ongoing adjuvant treatment studies that are comparing anthracy-
cline-based vs taxane-based chemotherapy such as the NSABP-B49 
clinical trial.
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